Mizuho Initiates Coverage On Tectonic Therapeutic with Outperform Rating, Announces Price Target of $51
Real-time Intelligence: Benzinga Pro offers the fastest news alerts and real-time intelligence for traders to enhance their market performance.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and accurate stock market insights.
Trade with 70% Backtested Accuracy
Analyst Views on TECX
About TECX
About the author
Tectonic Therapeutics to Host TX2100 Virtual KOL Event
- TX2100 Clinical Trial Progress: Tectonic Therapeutics is set to initiate a Phase 1a clinical trial of TX2100 in healthy volunteers in Q1 2026, positioning TX2100 as a potential first-in-class GPCR antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), addressing a significant unmet medical need with no approved therapies currently available.
- KOL Event Announcement: The company will host a virtual KOL event on February 24, 2026, featuring Dr. Hanny Al-Samkari from Harvard Medical School, who will discuss the mechanistic rationale and clinical context of TX2100, aiming to enhance awareness of HHT and advance the clinical development of TX2100.
- HHT Disease Background: HHT is a rare inherited vascular disorder affecting approximately 75,000 individuals, characterized by recurrent bleeding and the risk of arteriovenous malformations in vital organs, highlighting the urgent need for effective treatments, with TX2100 potentially improving patient quality of life.
- Scientist Background Introduction: Dr. Hanny Al-Samkari, the Peggy S. Blitz Endowed Chair in Hematology/Oncology at Massachusetts General Hospital, focuses on clinical research for bleeding disorders like HHT, and his role as Chair of the Cure HHT Global Research and Medical Advisory Board will provide critical expertise for the clinical development of TX2100.
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
TECX, GKOS, GH, ALGN, NMRA Experience After-Hours Surge Following Clinical Data and Earnings Reports
Tectonic Therapeutics Surge: Tectonic Therapeutic Inc. (TECX) saw a significant increase of 30.93% after announcing positive results from its Phase 1b trial of TX45 for pulmonary hypertension, improving heart function and hemodynamics.
Glaukos Corp. Performance: Glaukos Corp. (GKOS) rose 15.45% following a report of third-quarter net sales of $133.5 million, a 38% year-over-year increase, despite a net loss that improved from the previous year.
Guardant Health Gains: Guardant Health Inc. (GH) experienced a 19.29% increase in after-hours trading, reporting a 39% rise in third-quarter revenue to $265.2 million and narrowing its net loss compared to last year.
Align Technology Growth: Align Technology, Inc. (ALGN) shares jumped 15.15% after reporting a third-quarter net income of $56.8 million, with expectations for sequential revenue growth in the fourth quarter.
Three Biotech Stocks Rated 'Strong Buy' by Analysts with Potential Upside Exceeding 300%
Strong Buy Ratings: Three biotech stocks—Voyager Therapeutics, Tectonic Therapeutics, and Cullinan Management—are receiving "Strong Buy" ratings from analysts, indicating strong long-term growth potential in their respective markets.
Growth Projections: Voyager Therapeutics is projected to rise over 402%, Tectonic Therapeutics by 356%, and Cullinan Management by 316%, despite recent declines in their stock prices, highlighting significant upside potential if they successfully advance their pipelines.
Oppenheimer Begins Coverage of Tectonic Therapeutics with Outperform Rating and Sets Price Target at $80
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to enhance their market strategies and decision-making.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to unique stories and insights from Benzinga reporters.
Tectonic Therapeutics to Attend Investor Conferences in September
Company Overview: Tectonic Therapeutic, Inc. is a clinical-stage biotechnology firm focused on developing therapeutic proteins and antibodies that target G-protein coupled receptors (GPCRs).
Upcoming Conferences: The company will participate in three investor conferences in September 2025, including the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley's Annual Global Healthcare Conference.
Presentation Details: Key executives, including the CFO and CEO, will present during fireside chats at the Cantor and Morgan Stanley conferences, with webcasts available for investors.
Investor Engagement: Tectonic management will hold one-on-one meetings at these conferences, encouraging interested investors to coordinate through their respective financial representatives.
Tectonic Therapeutics to Host TX2100 Virtual KOL Event
- TX2100 Clinical Trial Progress: Tectonic Therapeutics is set to initiate a Phase 1a clinical trial of TX2100 in healthy volunteers in Q1 2026, positioning TX2100 as a potential first-in-class GPCR antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), addressing a significant unmet medical need with no approved therapies currently available.
- KOL Event Announcement: The company will host a virtual KOL event on February 24, 2026, featuring Dr. Hanny Al-Samkari from Harvard Medical School, who will discuss the mechanistic rationale and clinical context of TX2100, aiming to enhance awareness of HHT and advance the clinical development of TX2100.
- HHT Disease Background: HHT is a rare inherited vascular disorder affecting approximately 75,000 individuals, characterized by recurrent bleeding and the risk of arteriovenous malformations in vital organs, highlighting the urgent need for effective treatments, with TX2100 potentially improving patient quality of life.
- Scientist Background Introduction: Dr. Hanny Al-Samkari, the Peggy S. Blitz Endowed Chair in Hematology/Oncology at Massachusetts General Hospital, focuses on clinical research for bleeding disorders like HHT, and his role as Chair of the Cure HHT Global Research and Medical Advisory Board will provide critical expertise for the clinical development of TX2100.
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
TECX, GKOS, GH, ALGN, NMRA Experience After-Hours Surge Following Clinical Data and Earnings Reports
Tectonic Therapeutics Surge: Tectonic Therapeutic Inc. (TECX) saw a significant increase of 30.93% after announcing positive results from its Phase 1b trial of TX45 for pulmonary hypertension, improving heart function and hemodynamics.
Glaukos Corp. Performance: Glaukos Corp. (GKOS) rose 15.45% following a report of third-quarter net sales of $133.5 million, a 38% year-over-year increase, despite a net loss that improved from the previous year.
Guardant Health Gains: Guardant Health Inc. (GH) experienced a 19.29% increase in after-hours trading, reporting a 39% rise in third-quarter revenue to $265.2 million and narrowing its net loss compared to last year.
Align Technology Growth: Align Technology, Inc. (ALGN) shares jumped 15.15% after reporting a third-quarter net income of $56.8 million, with expectations for sequential revenue growth in the fourth quarter.
Three Biotech Stocks Rated 'Strong Buy' by Analysts with Potential Upside Exceeding 300%
Strong Buy Ratings: Three biotech stocks—Voyager Therapeutics, Tectonic Therapeutics, and Cullinan Management—are receiving "Strong Buy" ratings from analysts, indicating strong long-term growth potential in their respective markets.
Growth Projections: Voyager Therapeutics is projected to rise over 402%, Tectonic Therapeutics by 356%, and Cullinan Management by 316%, despite recent declines in their stock prices, highlighting significant upside potential if they successfully advance their pipelines.
Oppenheimer Begins Coverage of Tectonic Therapeutics with Outperform Rating and Sets Price Target at $80
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to enhance their market strategies and decision-making.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to unique stories and insights from Benzinga reporters.
Tectonic Therapeutics to Attend Investor Conferences in September
Company Overview: Tectonic Therapeutic, Inc. is a clinical-stage biotechnology firm focused on developing therapeutic proteins and antibodies that target G-protein coupled receptors (GPCRs).
Upcoming Conferences: The company will participate in three investor conferences in September 2025, including the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley's Annual Global Healthcare Conference.
Presentation Details: Key executives, including the CFO and CEO, will present during fireside chats at the Cantor and Morgan Stanley conferences, with webcasts available for investors.
Investor Engagement: Tectonic management will hold one-on-one meetings at these conferences, encouraging interested investors to coordinate through their respective financial representatives.
